Literature DB >> 8490716

Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis.

L H Parsons1, J B Justice.   

Abstract

The effects of local application of serotonin (5-HT) on extracellular levels of dopamine (DA) in the nucleus accumbens (N. ACC) were assessed using in vivo microdialysis. At a perfusate flow rate of 0.3 microliter/min the baseline dialysate concentration of DA was 2.1 +/- 0.7 nM (mean +/- S.E.M.; n = 5) and significantly increased to 142 +/- 18%, 220 +/- 47% and 332 +/- 35% of baseline when 0.1 microM, 0.2 microM and 0.4 microM concentrations of 5-HT were included in the perfusate. Perfusate 5-HT concentrations below 0.1 microM had no effect on dialysate DA. The in vivo dialysis efficiency for 5-HT was found to be 39 +/- 12%, and thus the concentrations of 5-HT reaching the extracellular space at the surface of the dialysis membrane were estimated to be 40, 80 and 160 nM for the 0.1, 0.2 and 0.4 microM 5-HT perfusates, respectively. The serotonin-induced increase in dialysate DA was attenuated by co-perfusion of 0.4 microM 5-HT with 4 microM concentrations of pindolol (a relatively non-specific 5-HT1 antagonist; 151 +/- 7% vs. 332 +/- 35% baseline dialysate DA for 5-HT/antagonist and 5-HT-only perfusates, respectively), LY 53,857 (a specific 5-HT2 antagonist; 130 +/- 17% vs. 332 +/- 35%) and MDL 7222 (a specific 5-HT3 antagonist; 143 +/- 19% vs. 332 +/- 35%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490716     DOI: 10.1016/0006-8993(93)90984-u

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  40 in total

1.  Involvement of 5-HT(3) receptors in the nucleus accumbens in the potentiation of cocaine-induced behaviours in the rat.

Authors:  S Herges; D A Taylor
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Opponency revisited: competition and cooperation between dopamine and serotonin.

Authors:  Y-Lan Boureau; Peter Dayan
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

Review 3.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

4.  MDMA induced dopamine release in vivo: role of endogenous serotonin.

Authors:  S Koch; M P Galloway
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.

Authors:  George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2017-01-03       Impact factor: 4.530

6.  [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials.

Authors:  Oliver Pogarell; Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

7.  The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum.

Authors:  G G Nomikos; L Arborelius; B B Höök; U Hacksell; T H Svensson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Drug addiction: functional neurotoxicity of the brain reward systems.

Authors:  F Weiss; G F Koob
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

9.  Injection of 5-HT into the nucleus accumbens reduces the effects of d-amphetamine on responding for conditioned reward.

Authors:  P J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

10.  Consequences of post-weaning social isolation on anxiety behavior and related neural circuits in rodents.

Authors:  Jodi L Lukkes; Michael J Watt; Christopher A Lowry; Gina L Forster
Journal:  Front Behav Neurosci       Date:  2009-08-20       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.